Table 2. Progress of islet imaging on MRI.
| Year | References | MRI condition | Strength in scanners | Donor | Recipient | Contrast agent | Comments |
| 2004 | 37 | T2WI | 4.7T | rat | rat | Resovist® | The first study for MRI imaging |
| 2005 | 39 | T2WI | 4.7T | rat (allo) | rat | Resovist® | Rejection model on MRI |
| 2006 | 41 | T2WI | 4.7T | human | mouse (immune deficient) |
SPIO (MN-NIRF) |
Certified islets both on MRI and in histological staining |
| 2006 | 46 | T2WI | 1.5T | rat | rat | Feridex® with poly-l-lysine | Availability of clinical MRI Few toxic agents |
| 2007 | 43 | T1WI | 7T | mouse and human | mouse (immune deficient) |
Gd | The first study of T1WI MRI |
| 2007 | 60 | T1 and T2WI | 11.7T | mouse | mouse | Feridex® and Gd | Visualized islets by Feridex® labeling and vessels around islets by Gd enhancement |
| 2007 | 64 | T2WI | 3T | human | pig | Feridex® (encapsulated islets) | MRI for large animals |
| 2008 | 66 | T2WI | 1.5T | human | human | Resovist® | The first clinical success of MRI imaging |
| 2009 | 54 | T2WI | 4.7T | rat | rat (allo) |
Feridex®, Resovist®, Endorem® | Evaluation of toxicity in various SPIOs |
| 2009 | 65 | T2WI | 1.5T | baboon | baboon (auto) | Feridex® | Autotranplantation model using non-human primates |
| 2010 | 67 | T2WI | 3T | human | human | Resovist® | Clinical MRI imaging |
| 2011 | 53 | T2WI | 1.5T | rat | mouse (immune deficient |
Feridex® with heparin | Lower toxicity Improving engraftment |